Enfermedades infecciosas y microbiologia clinica最新文献

英文中文

Dalbavancin: A new milestone in the treatment of Gram-positive infections

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.eimc.2024.12.004

Arístides de Alarcón González

引用次数: 0

Evolving SARS-CoV-2 severity among hospital and university affiliates in Spain and Greater Boston 西班牙和大波士顿地区医院和大学附属机构中 SARS-CoV-2 严重程度的变化

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2023.12.011

Fares Amer , Fan-Yun Lan , Mario Gil-Conesa , Amalia Sidossis , Daniel Bruque , Eirini Iliaki , Jane Buley , Neetha Nathan , Lou Ann Bruno-Murtha , Silvia Carlos , Stefanos N. Kales , Alejandro Fernandez-Montero

Introduction

The COVID-19 pandemic caused by the SARS-CoV-2 virus greatly affected healthcare workers and healthcare systems. It also challenged schools and universities worldwide negatively affecting in-person education. We conducted this study is to assess the evolution of SARs-CoV-2 virulence over the course of the pandemic.

Methods

A combined cohort of University students in Spain and HCWs from the two hospitals in Spain, and one healthcare system in the Greater Boston area was followed prospectively from March 8th, 2020, to January 31st, 2022 for diagnosis with COVID-19 by PCR testing and related sequelae. Follow-up time was divided into four periods according to distinct waves of infection during the pandemic. Severity of COVID-19 was measured by case-hospitalization rate. Descriptive statistics and multivariable-adjusted statistics using the Poisson mixed-effects regression model were applied. As a sensitivity analysis, information on SARS-CoV-2 RNA in wastewater and COVID-19 deaths through May 30, 2023 from the Boston area was collected.

Results

For the last two periods of the study (January 1st to December 15th, 2021 and December 16th, 2021 to January 31st, 2022) and relative to the first period (March 8th to May 31st, 2020), the incidence rate ratios (IRRs) of hospitalization were 0.08 (95% CI, 0.03–0.17) and 0.03 (95% CI, 0.01–0.15), respectively. In addition, a relative risk 0.012 CI95% (0.012–0.012) was observed when comparing COVID-19 mortality versus SARS-CoV-2 RNA copies/mL in Boston-area wastewater over the period (16th December 2021 to 30th May 2023) and relative to the first period.

Conclusions

The severity of COVID-19 and immunity of our populations evolved over time, resulting in a decrease in case severity. We found the case-hospitalization rate decreased more than 90% in our cohort despite an increase in incidence.

导言SARS-CoV-2 病毒引发的 COVID-19 大流行对医护人员和医疗系统造成了极大的影响。它还对世界各地的学校和大学提出了挑战，对现场教育造成了负面影响。从 2020 年 3 月 8 日到 2022 年 1 月 31 日，我们对西班牙的大学生和来自西班牙两家医院以及大波士顿地区一家医疗保健系统的医护人员进行了前瞻性随访，通过 PCR 检测确诊他们感染了 COVID-19，并发现了相关后遗症。随访时间根据大流行期间不同的感染波分为四个阶段。COVID-19 的严重程度通过病例住院率来衡量。采用泊松混合效应回归模型进行描述性统计和多变量调整统计。作为一项敏感性分析，收集了波士顿地区截至 2023 年 5 月 30 日的废水中 SARS-CoV-2 RNA 和 COVID-19 死亡病例的信息。结果在研究的最后两个阶段（2021 年 1 月 1 日至 12 月 15 日和 2021 年 12 月 16 日至 2022 年 1 月 31 日），相对于第一个阶段（2020 年 3 月 8 日至 5 月 31 日），住院发病率比（IRR）分别为 0.08（95% CI，0.03-0.17）和 0.03（95% CI，0.01-0.15）。此外，比较波士顿地区废水中 COVID-19 死亡率与 SARS-CoV-2 RNA 拷贝数/毫升在 2021 年 12 月 16 日至 2023 年 5 月 30 日期间以及相对于第一个期间的相对风险 0.012 CI95% (0.012-0.012)。我们发现，尽管发病率有所上升，但我们队列中的病例住院率却下降了 90% 以上。

{"title":"Evolving SARS-CoV-2 severity among hospital and university affiliates in Spain and Greater Boston","authors":"Fares Amer , Fan-Yun Lan , Mario Gil-Conesa , Amalia Sidossis , Daniel Bruque , Eirini Iliaki , Jane Buley , Neetha Nathan , Lou Ann Bruno-Murtha , Silvia Carlos , Stefanos N. Kales , Alejandro Fernandez-Montero","doi":"10.1016/j.eimc.2023.12.011","DOIUrl":"10.1016/j.eimc.2023.12.011","url":null,"abstract":"<div><h3>Introduction</h3><div>The COVID-19 pandemic caused by the SARS-CoV-2 virus greatly affected healthcare workers and healthcare systems. It also challenged schools and universities worldwide negatively affecting in-person education. We conducted this study is to assess the evolution of SARs-CoV-2 virulence over the course of the pandemic.</div></div><div><h3>Methods</h3><div>A combined cohort of University students in Spain and HCWs from the two hospitals in Spain, and one healthcare system in the Greater Boston area was followed prospectively from March 8th, 2020, to January 31st, 2022 for diagnosis with COVID-19 by PCR testing and related sequelae. Follow-up time was divided into four periods according to distinct waves of infection during the pandemic. Severity of COVID-19 was measured by case-hospitalization rate. Descriptive statistics and multivariable-adjusted statistics using the Poisson mixed-effects regression model were applied. As a sensitivity analysis, information on SARS-CoV-2 RNA in wastewater and COVID-19 deaths through May 30, 2023 from the Boston area was collected.</div></div><div><h3>Results</h3><div>For the last two periods of the study (January 1st to December 15th, 2021 and December 16th, 2021 to January 31st, 2022) and relative to the first period (March 8th to May 31st, 2020), the incidence rate ratios (IRRs) of hospitalization were 0.08 (95% CI, 0.03–0.17) and 0.03 (95% CI, 0.01–0.15), respectively. In addition, a relative risk 0.012 CI95% (0.012–0.012) was observed when comparing COVID-19 mortality versus SARS-CoV-2 RNA copies/mL in Boston-area wastewater over the period (16th December 2021 to 30th May 2023) and relative to the first period.</div></div><div><h3>Conclusions</h3><div>The severity of COVID-19 and immunity of our populations evolved over time, resulting in a decrease in case severity. We found the case-hospitalization rate decreased more than 90% in our cohort despite an increase in incidence.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 1","pages":"Pages 17-22"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139666939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.07.015

Luana Silva Dornelles , Mariana Preussler Mott , Gabriela da Silva Collar , Luciana Giordani , Rodrigo Minuto Paiva , Larissa Lutz

Introduction

Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.

Methods

We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25–27 mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).

Results

We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime–avibactam (72.7%), meropenem–vaborbactam (100%), imipenem–relebactam (63.6%) and ceftolozane–tazobactam (36.4%).

Conclusion

We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.

{"title":"Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem","authors":"Luana Silva Dornelles , Mariana Preussler Mott , Gabriela da Silva Collar , Luciana Giordani , Rodrigo Minuto Paiva , Larissa Lutz","doi":"10.1016/j.eimc.2024.07.015","DOIUrl":"10.1016/j.eimc.2024.07.015","url":null,"abstract":"<div><h3>Introduction</h3><div>Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.</div></div><div><h3>Methods</h3><div>We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25–27mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).</div></div><div><h3>Results</h3><div>We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime–avibactam (72.7%), meropenem–vaborbactam (100%), imipenem–relebactam (63.6%) and ceftolozane–tazobactam (36.4%).</div></div><div><h3>Conclusion</h3><div>We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 1","pages":"Pages 32-35"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A man with recurrent axillary abscess 一名患有复发性腋窝脓肿的男子

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.03.012

Gamze Durmaz , Esin Beycan , Abdurrahman Kaya , Ali Mert

引用次数: 0

New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.08.012

Pilar Arrazola , María Fernández Prada , Ángel Gil , José Gómez Rial , Cristina Hernán , Rosario Menéndez , Antoni Trilla , Raúl Ortiz de Lejarazu

Despite high initial vaccination rates, Spain's current COVID-19 vaccination coverage in recommended groups does not meet WHO targets. For the upcoming season, challenges include revising vaccination age, updating risk groups, and unifying criteria with flu vaccine co-administration. European Commission's advance purchase agreements limit access to certain vaccines, and the need for vaccines effective against current variants adds administrative complexities. Spain's COVID-19 vaccination recommendations should adapt to these specific circumstances. Using vaccines effective against predominant variants with appropriate response duration is crucial to protect at-risk populations. Enhancing training and health education campaigns for health professionals and the general public, alongside utilizing tools to simplify vaccination recommendations, can promote higher vaccination rates in Spain. Addressing these challenges is essential to ensure adequate protection and improve vaccination coverage, ultimately achieving better public health outcomes in the face of evolving COVID-19 threats.

{"title":"New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons","authors":"Pilar Arrazola , María Fernández Prada , Ángel Gil , José Gómez Rial , Cristina Hernán , Rosario Menéndez , Antoni Trilla , Raúl Ortiz de Lejarazu","doi":"10.1016/j.eimc.2024.08.012","DOIUrl":"10.1016/j.eimc.2024.08.012","url":null,"abstract":"<div><div>Despite high initial vaccination rates, Spain's current COVID-19 vaccination coverage in recommended groups does not meet WHO targets. For the upcoming season, challenges include revising vaccination age, updating risk groups, and unifying criteria with flu vaccine co-administration. European Commission's advance purchase agreements limit access to certain vaccines, and the need for vaccines effective against current variants adds administrative complexities. Spain's COVID-19 vaccination recommendations should adapt to these specific circumstances. Using vaccines effective against predominant variants with appropriate response duration is crucial to protect at-risk populations. Enhancing training and health education campaigns for health professionals and the general public, alongside utilizing tools to simplify vaccination recommendations, can promote higher vaccination rates in Spain. Addressing these challenges is essential to ensure adequate protection and improve vaccination coverage, ultimately achieving better public health outcomes in the face of evolving COVID-19 threats.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 1","pages":"Pages 36-46"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

¿Debemos implantar un marcapasos a todo paciente joven con bloqueo auriculoventricular de alto grado? La importancia de la sospecha clínica en la carditis de Lyme

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.07.004

Ester Minguez de la Guía, Macarena López Vázquez, Pablo Miguel Valentín García, Miguel José Corbi Pascual

引用次数: 0

Accidental intravenous probiotic injection in an immunocompromised patient: Implications and consequences

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.08.004

Idoia Bilbao , María Pascual , José Ramón Yuste , José Luis del Pozo

引用次数: 0

Screening for Crimean-Congo Haemorrhagic Fever Virus antibodies in humans living in an endemic area of Spain

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.09.006

Helena Miriam Lorenzo Juanes , Montserrat Alonso-Sardón , Belen Vicente , Beatriz Rodríguez Alonso , Amparo López-Bernus , Josue Pendones Ulerio , Rufino Alamo Sanz , Antonio Muro , Juan Luis Muñoz Bellido , Moncef Belhassen-García

Introduction

Crimean-Congo haemorrhagic fever (CCHF) is an emerging tick-borne viral disease. It has been described in Spain in both ticks and humans. Until July 2024 most cases have been described in the central-western part of the Iberian Peninsula. This study aims to assess the seroprevalence of antibodies against CCHF virus (CCHFV) in humans in the area that has reported the highest number of cases in Spain.

Methods

The study was conducted to estimate the seroprevalence of antibodies against CCHFV antibodies among patients referred to a hospital located in the central-western area of Spain, an endemic area for CCHFV of Spain. Patients were recruited from April 1, 2023, to June 30, 2023. A commercial ELISA was used to detect serum antibodies against the CCHFV.

Results

We screened 658 samples from 370 (56.2%) men, with a mean (±SD) age of 58.6 years (±14.3). Of these, 4 were IgG positive, representing an IgG seropositivity of 0.6% (95% CI, 0.01–1.19). None of these four patients recalled having a clinical picture that strongly suggested CCHF.

Over the study period, in the population analysed in an area with circulation of CCHFV the seroprevalence of antibodies was 0.6%.

Conclusion

Our results suggest active circulation of the virus in humans in western Spain. Although the risk of developing CCHF is currently considered low, physicians should be alert to the imminent possibility of developing new cases of CCHF.

{"title":"Screening for Crimean-Congo Haemorrhagic Fever Virus antibodies in humans living in an endemic area of Spain","authors":"Helena Miriam Lorenzo Juanes , Montserrat Alonso-Sardón , Belen Vicente , Beatriz Rodríguez Alonso , Amparo López-Bernus , Josue Pendones Ulerio , Rufino Alamo Sanz , Antonio Muro , Juan Luis Muñoz Bellido , Moncef Belhassen-García","doi":"10.1016/j.eimc.2024.09.006","DOIUrl":"10.1016/j.eimc.2024.09.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Crimean-Congo haemorrhagic fever (CCHF) is an emerging tick-borne viral disease. It has been described in Spain in both ticks and humans. Until July 2024 most cases have been described in the central-western part of the Iberian Peninsula. This study aims to assess the seroprevalence of antibodies against CCHF virus (CCHFV) in humans in the area that has reported the highest number of cases in Spain.</div></div><div><h3>Methods</h3><div>The study was conducted to estimate the seroprevalence of antibodies against CCHFV antibodies among patients referred to a hospital located in the central-western area of Spain, an endemic area for CCHFV of Spain. Patients were recruited from April 1, 2023, to June 30, 2023. A commercial ELISA was used to detect serum antibodies against the CCHFV.</div></div><div><h3>Results</h3><div>We screened 658 samples from 370 (56.2%) men, with a mean (±SD) age of 58.6 years (±14.3). Of these, 4 were IgG positive, representing an IgG seropositivity of 0.6% (95% CI, 0.01–1.19). None of these four patients recalled having a clinical picture that strongly suggested CCHF.</div><div>Over the study period, in the population analysed in an area with circulation of CCHFV the seroprevalence of antibodies was 0.6%.</div></div><div><h3>Conclusion</h3><div>Our results suggest active circulation of the virus in humans in western Spain. Although the risk of developing CCHF is currently considered low, physicians should be alert to the imminent possibility of developing new cases of CCHF.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 1","pages":"Pages 23-27"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

More threats: The increase in tick-borne diseases and their spectrum

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.10.001

José A. Oteo, Ana M. Palomar

引用次数: 0

A simple MALDI–TOF-MS method for the identification of non-mycobacterial aerobic actinomycetes growing on blood agar subcultures from positive MGIT cultures

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.eimc.2024.08.009

Maria Jose Muñoz Davila , Maria Teresa Cabezas Fernandez , Ana Belen Esteban García , Miguel José Martinez Lirola

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Enfermedades infecciosas y microbiologia clinica

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀